A curated public database designed to represent, store, and analyze the divergent forms of data underlying HIV drug resistance.

NVP Resistance Mutations in Treatment-naive Patients with Subtypes A, C, and D
Church JD, Hudelson SE, Guay LA, Chen S, Hoover DR, Parkin N, Fiscus SA, Mmiro F, Musoke P, Kumwenda N, Jackson JB, Taha TE, Eshleman SH. HIV type 1 variants with nevirapine resistance mutations are rarely detected in antiretroviral drug-naive African women with subtypes A, C, and D. AIDS Research and Human Retroviruses 2008 Jan;24(1):7-14.

Genotypes from Santos, Brazil
de Sa-Filho DJ, Da Silva Soares M, Candido V, Gagliani LH, Cavaliere E, Diaz RS, Caseiro MM. HIV Type 1 pol Gene Diversity and Antiretroviral Drug Resistance Mutations in Santos, Brazil AIDS Research and Human Retroviruses 2008 Mar;24(3):347-53.

Elvitegravir, Raltegravir and L870,810 Phenotypes
Hombrouck A, Voet A, Van Remoortel B, Desadeleer C, De Maeyer M, Debyser Z, Witvrouw M. Mutations in human immunodeficiency virus type 1 integrase confer resistance to the naphthyridine L-870,810 and cross-resistance to the clinical trial drug GS-9137 Antimicrobial Agents and Chemotherapy< 2008 Jun;52(6):2069-78.

Genotypes from Nagoya, Japan, 1999-2006
Ibe S, Hattori J, Fujisaki S, Shigemi U, Fujisaki S, Shimizu K, Nakamura K, Kazumi T, Yokomaku Y, Mamiya N, Hamaguchi M, Kaneda T. Trend of drug-resistant HIV type 1 emergence among therapy-naive patients in Nagoya, Japan: an 8-year surveillance from 1999 to 2006 AIDS Research and Human Retroviruses 2008 Jan;24(1):7-14.

Genotypes from Patients who Failed Raltegravir Treatment
Malet I, Delelis O, Valantin MA, Montes B, Soulie C, Wirden M, Tchertanova L, Peytavin G, Reynes J, Mouscadet JF, Katlama C, Calvez V, Marcelin AG. Mutations Associated with Failure of Raltegravir Treatment affect integrase sensitivity to the inhibitor in vitro Antimicrobial Agents and Chemotherapy< 2008 Apr;52(4):1351-8.

Genotypes from Patients from KwaZulu Natal, South Africa after First-Time ARV Treatment
Marconi VC, Sunpath H, Lu Z, Gordon M, Koranteng-Apeagyei K, Hampton J, Carpenter S, Giddy J, Ross D, Holst H, Losina E, Walker BD, Kuritzkes DR. Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa Clinical Infectious Disease 2008 May 15;46(10):1589-97.

Genotypes from the Southern Central African Republic
Punzi G, Saracino A, Brindicci G, Scarabaggio T, Lagioia A, Angarano G, Monno L. HIV infection and protease genetic diversity in a rural area of the Southern Central African Republic Journal of Medical Virology 2005 Dec;77(4):457-9.

Integrase Inhibitor Phenotypes
Ren C, May S, Miletti T, Bedard J. In vitro Cross-resistance Studies of Five Different Classes of Integrase Inhibitors in Recombinant HIV-1 Antiviral Therapy 2007 12:S3 (abstract no. 1).

The Discovery of Raltegravir
Rowley M. The Discovery of Raltegravir, an Integrase Inhibitor for the Treatment of HIV Infection Progress in Medicinal Chemistry 2008;46:1-28.

Genotypes from Newly Diagnosed Patients from Belgium, 2003-2006
Vercauteren J, Derdelinckx I, Sasse A, Bogaert M, Ceunen H, De Roo A, De Wit S, Deforche K, Echahidi F, Fransen K, Goffard JC, Goubau P, Goudeseune E, Yombi JC, Lacor P, Liesnard C, Moutschen M, Pierard D, Rens R, Schrooten Y, Vaira D, Van Den Heuvel A, Van Der Gucht B, Van Ranst M, Van Wijngaerden E, Vandercam B, Vekemans M, Verhofstede C, Clumeck N, Vandamme AM, Van Laethem K. Prevalence and Epidemiology of HIV Type 1 Drug Resistance among Newly Diagnosed Therapy-Naive Patients in Belgium from 2003 to 2006 AIDS Research and Human Retroviruses 2008 Mar;24(3):355-62.